Tarsus officer's spouse plans $278K share sale

Rule 144 notice reports planned sale of 3,180 Tarsus common shares from the account of the spouse of a company officer, along with prior recent sales.

Rhea-AI Filing Summary

Tarsus Pharmaceuticals, Inc. (TARS) received a Rule 144 notice indicating an intention to sell restricted or control securities. The notice covers a planned sale of 3,180 shares of Tarsus common stock through Fidelity Brokerage Services LLC on Nasdaq. The filing states that the shares are in the account of Stephen H. Lin, the spouse of company officer Elizabeth Yeu-Lin. It also notes prior sales from the same account over the past three months and lists 43,882,996 Tarsus common shares outstanding as of September 4, 2026.

Key Figures

Shares planned for sale: 3,180 shares Stated value of planned sale: 278,250.00 Shares outstanding: 43,882,996 shares +2 more

5 metrics

Shares planned for sale 3,180 shares Planned sale of Tarsus common stock referenced in the Rule 144 notice

Stated value of planned sale 278,250.00 Amount listed for the 3,180 shares in the securities information section

Shares outstanding 43,882,996 shares Tarsus common shares outstanding as of September 4, 2026

Past sale September 1, 2026 4,601 shares; 339,829.86 Sale of Tarsus common stock attributed to Elizabeth Yeu-Lin

Past sales September 2, 2026 5,387 shares; 446,010.00 and 1,590 shares; 127,200.00 Sales of Tarsus common stock by Elizabeth Yeu-Lin and Stephen H. Lin

Key Terms

Rule 144, Open Market Purchase, attorney-in-fact, Member of immediate family

4 terms

Rule 144 regulatory

"See the definition of "person" in paragraph (a) of Rule 144."

Rule 144 is a U.S. securities regulation that sets conditions under which restricted or insider-held shares can be legally resold to the public, such as required holding periods, availability of public information, limits on how much can be sold at once, and certain filing requirements. For investors it matters because it determines when previously locked-up shares can enter the market — like a release valve that can increase supply, affect share price, and signal insider intent.

Open Market Purchase financial

"Common | 09/14/2022 | Open Market Purchase | Issuer"

An open market purchase is when a company buys its own shares on public stock exchanges the same way any investor would, rather than through a private deal. Investors care because these purchases reduce the number of shares available, can boost earnings per share and share price, signal that management thinks the stock is undervalued, and use company cash that might otherwise go to reinvestment or dividends — like a business quietly buying back its own tickets at the box office.

attorney-in-fact regulatory

"as attorney-in-fact for Elizabeth Yeu-Lin."

An attorney-in-fact is the person or entity given legal authority through a power of attorney to act on behalf of another for specific tasks, such as signing documents, voting shares, or handling transactions. For investors, this matters because it lets a trusted representative make timely decisions or complete paperwork when the owner cannot, much like handing keys to someone to run errands on your behalf—so checks on scope and limits of that authority are important.

Member of immediate family regulatory

"Member of immediate family of any of the foregoing"

FAQ

What does the Rule 144 notice disclose about planned TARS share sales?

The notice discloses an intention to sell 3,180 shares of Tarsus Pharmaceuticals, Inc. common stock through Fidelity Brokerage Services LLC on Nasdaq, as reflected in the Rule 144 filing dated September 4, 2026.

Who is associated with the TARS shares covered by this Rule 144 filing?

The shares are in the account of Stephen H. Lin, who is the spouse of Elizabeth Yeu-Lin, an officer of Tarsus Pharmaceuticals, Inc., as stated in the remarks section of the notice.

How many TARS shares were sold from the same account in the past three months?

The filing lists past three-month sales of 4,601 shares on September 1, 2026, 5,387 shares on September 2, 2026 by Elizabeth Yeu-Lin, and 1,590 shares on September 2, 2026 by Stephen H. Lin.

What share count for Tarsus Pharmaceuticals, Inc. is referenced in the Rule 144 filing?

The securities information section references 43,882,996 shares of Tarsus Pharmaceuticals, Inc. common stock outstanding as of September 4, 2026.

What values are associated with the TARS shares in this Rule 144 filing?

For the planned sale of 3,180 shares, the filing lists a value of 278,250.00. Past three-month sales show stated values of 339,829.86, 446,010.00, and 127,200.00 for the respective transactions.

Who signed the Rule 144 notice related to TARS?

The notice is signed by /s/ Jessica Spraker, described as a duly authorized representative of Fidelity Brokerage Services LLC, acting as attorney-in-fact for Elizabeth Yeu-Lin.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/04/2026 - 04:03 PM Accepted by SEC EDGAR 09/04/2026 - 04:03 PM Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001842190
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	Tarsus Pharmaceuticals, Inc.
SEC File Number	001-39614
Address of Issuer	15440 LAGUNA CANYON ROAD IRVINE CALIFORNIA 92618
Phone	(949) 409-9820
Name of Person for Whose Account the Securities are To Be Sold	Lin Elizabeth Yeu
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Member of immediate family of any of the foregoing

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Fidelity Brokerage Services LLC 900 Salem Street Smithfield RI 02917	3180	278250.00	43882996	09/04/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	09/14/2022	Open Market Purchase	Issuer			3180	09/14/2022	Cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Elizabeth Yeu-Lin 17700 Laguna Canyon Road Floor 4 Irvine CA 92618	Common	09/01/2026	4601	339829.86
Elizabeth Yeu-Lin 17700 Laguna Canyon Road Floor 4 Irvine CA 92618	Common	09/02/2026	5387	446010.00
Stephen H. Lin 17700 Laguna Canyon Road Floor 4 Irvine CA 92618	Common	09/02/2026	1590	127200.00

144: Remarks and Signature

Remarks	Today's sale and sales from the past 3 months occurred in the account of Stephen H. Lin who is the spouse of Elizabeth Yeu-Lin, an officer of the company.
Date of Notice	09/04/2026
Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1	05/29/2026
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	/s/ Jessica Spraker, as a duly authorized representative of Fidelity Brokerage Services LLC, as attorney-in-fact for Elizabeth Yeu-Lin.
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)